ID   TOV-112D
AC   CVCL_3612
SY   TOV-112d; TOV112D; TOV-112; TOV112
DR   BTO; BTO:0005182
DR   CLO; CLO_0009384
DR   EFO; EFO_0005263
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-11731
DR   BCRC; 60408
DR   BioGRID_ORCS_Cell_line; 201
DR   BioSample; SAMN03471348
DR   BioSample; SAMN10988342
DR   cancercelllines; CVCL_3612
DR   Cell_Model_Passport; SIDM01170
DR   ChEMBL-Cells; CHEMBL3707165
DR   ChEMBL-Targets; CHEMBL3707166
DR   Cosmic; 875292
DR   Cosmic; 1066219
DR   Cosmic; 1102818
DR   Cosmic; 1113278
DR   Cosmic; 1139220
DR   Cosmic; 1305335
DR   Cosmic; 1709264
DR   Cosmic; 2186587
DR   Cosmic-CLP; 1299070
DR   DepMap; ACH-000048
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1299070
DR   GEO; GSE35972
DR   GEO; GSM274697
DR   GEO; GSM289383
DR   GEO; GSM289384
DR   GEO; GSM289387
DR   GEO; GSM289388
DR   GEO; GSM313690
DR   GEO; GSM659407
DR   GEO; GSM711721
DR   GEO; GSM784575
DR   GEO; GSM851944
DR   GEO; GSM887710
DR   GEO; GSM888803
DR   GEO; GSM1001425
DR   GEO; GSM1001426
DR   GEO; GSM1001489
DR   GEO; GSM1291152
DR   GEO; GSM1340594
DR   GEO; GSM1341134
DR   GEO; GSM1374964
DR   GEO; GSM1670546
DR   IARC_TP53; 20197
DR   LiGeA; CCLE_580
DR   LINCS_LDP; LCL-1920
DR   PharmacoDB; TOV112D_1604_2019
DR   PRIDE; PXD003668
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3612
DR   PubChem_Cell_line; CVCL_3612
DR   Wikidata; Q54972795
RX   Patent=US5710038;
RX   PubMed=10949993;
RX   PubMed=11641787;
RX   PubMed=16380993;
RX   PubMed=18507860;
RX   PubMed=19058220;
RX   PubMed=19288585;
RX   PubMed=20204287;
RX   PubMed=22328975;
RX   PubMed=22460905;
RX   PubMed=22710073;
RX   PubMed=22931248;
RX   PubMed=24023729;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27235858;
RX   PubMed=27397505;
RX   PubMed=27561551;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=33328126;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11371.
CC   Population: Caucasian.
CC   Doubling time: 0.8 day (PubMed=10949993); 1.0 +- 0.2 days (PubMed=18507860); 22 hours (PubMed=25984343); 1.49 days (PubMed=22931248); 29.13 hours (GrayJW panel).
CC   HLA typing: A*03:01,03:01; B*14:01,14:01; C*08:02,08:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Ala (c.109T>G); ClinVar=VCV000376235; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Leu639fs (c.1915delC); Zygosity=Homozygous (PubMed=33328126; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10949993; PubMed=18507860; PubMed=20204287; PubMed=22931248; PubMed=24023729; PubMed=25230021; PubMed=33328126; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.33%; East Asian, North=2.98%; East Asian, South=0%; South Asian=0.16%; European, North=53.45%; European, South=43.09% (PubMed=30894373).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): ATCC; Cosmic-CLP; Direct_author_submission; PubMed=22710073; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,12 (ATCC; Cosmic-CLP; Direct_author_submission; PubMed=22710073; PubMed=25877200; PubMed=30485824)
ST   D16S539: 11,12 (PubMed=25230021)
ST   D18S51: 17
ST   D19S433: 14
ST   D21S11: 31
ST   D2S1338: 19,24
ST   D3S1358: 15
ST   D5S818: 10
ST   D7S820: 9,10
ST   D8S1179: 9,13
ST   FGA: 20
ST   Penta D: 9
ST   Penta E: 11
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   Patent=US5710038;
RA   Mes-Masson A.-M., Provencher D.M.;
RT   "Primary cultures of normal and tumoral human ovarian epithelium.";
RL   Patent number US5710038, 20-Jan-1998.
//
RX   PubMed=10949993; DOI=10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2;
RA   Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N.,
RA   Wang J.C., Eydoux P., Savoie R., Tonin P.N., Mes-Masson A.-M.;
RT   "Characterization of four novel epithelial ovarian cancer cell
RT   lines.";
RL   In Vitro Cell. Dev. Biol. Anim. 36:357-361(2000).
//
RX   PubMed=11641787; DOI=10.1038/sj.onc.1204804;
RA   Tonin P.N., Hudson T.J., Rodier F., Bossolasco M., Lee P.D., Novak J.,
RA   Manderson E.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Microarray analysis of gene expression mirrors the biology of an
RT   ovarian cancer model.";
RL   Oncogene 20:6617-6626(2001).
//
RX   PubMed=16380993; DOI=10.1002/ijc.21671;
RA   Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C.,
RA   Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.;
RT   "Selenium binding protein 1 in ovarian cancer.";
RL   Int. J. Cancer 118:2433-2440(2006).
//
RX   PubMed=18507860; DOI=10.1186/1471-2407-8-152;
RA   Ouellet V., Zietarska M., Portelance L., Lafontaine J., Madore J.,
RA   Puiffe M.-L., Arcand S.L., Shen Z., Hebert J., Tonin P.N.,
RA   Provencher D.M., Mes-Masson A.-M.;
RT   "Characterization of three new serous epithelial ovarian cancer cell
RT   lines.";
RL   BMC Cancer 8:152.1-152.18(2008).
//
RX   PubMed=19058220; DOI=10.1002/ijc.24058;
RA   Dafou D., Ramus S.J., Choi K., Grun B., Trott D.A., Newbold R.F.,
RA   Jacobs I.J., Jones C., Gayther S.A.;
RT   "Chromosomes 6 and 18 induce neoplastic suppression in epithelial
RT   ovarian cancer cells.";
RL   Int. J. Cancer 124:1037-1044(2009).
//
RX   PubMed=19288585; DOI=10.1002/elps.200800505;
RA   Dai L., Li C., Shedden K.A., Misek D.E., Lubman D.M.;
RT   "Comparative proteomic study of two closely related ovarian
RT   endometrioid adenocarcinoma cell lines using cIEF fractionation and
RT   pathway analysis.";
RL   Electrophoresis 30:1119-1131(2009).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=33328126; DOI=10.1016/j.ygyno.2020.12.004;
RA   Karnezis A.N., Chen S.Y.-T., Chow C., Yang W., Hendricks W.P.D.,
RA   Ramos P., Briones N., Mes-Masson A.-M., Bosse T., Gilks C.B.,
RA   Trent J.M., Weissman B.E., Huntsman D.G., Wang Y.-M.;
RT   "Re-assigning the histologic identities of COV434 and TOV-112D ovarian
RT   cancer cell lines.";
RL   Gynecol. Oncol. 160:568-578(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//